Aptamer Group plc

Equities

APTA

GB00BNRRP542

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:12 2024-05-22 am EDT			5-day change	1st Jan Change
0.775 ^GBX	+14.81%		+3.33%	-32.61%

May. 22	Aptamer Group Teams Up with Timser for First-ever Cervical Cancer Blood Test	MT
May. 22	Aptamer shares up on GBP465,000 cervical cancer contract with Timser	AN

Aptamer appoints Rob Quinn as new chief financial officer

February 13, 2023 at 02:52 am EST

Aptamer Group PLC - York, England-based company which develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications - Appoints Rob Quinn as chief financial and as an executive director of the board, effective from March 1. Quinn was previously CFO at Pharnext, a biotech company in Paris.

Chief Executive Officer Arron Tolley says: "I am very pleased to welcome Rob to the team at Aptamer as permanent CFO. Rob's background in the oligonucleotide space and experience as a CFO of AIM listed companies made him an ideal fit for this role. I look forward to working closely with him as we look to meet the rapidly expanding demand for antibody alternatives, deliver the next generation of our Optimer platform, and win global contracts across the life sciences sector."

Current stock price: 42.55 pence, up 6.4% in London on Monday morning

12 month change: down 68%

By Holly Beveridge; Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	APTAMER GROUP PLC	0.775 GBX	+14.81%	+3.33%	4.01M
	PHARNEXT SCA	0.0541 EUR	-3.57%	-11.89%	10.59K

Latest news about Aptamer Group plc

Aptamer Group Teams Up with Timser for First-ever Cervical Cancer Blood Test	May. 22	MT
Aptamer shares up on GBP465,000 cervical cancer contract with Timser	May. 22	AN
Aptamer says sales pipeline "strong" as reports strategic headway	May. 13	AN
EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings	Apr. 22	AN
Aptamer inks new Optimer+ transplant rejection therapy partnership	Apr. 18	AN
Aptamer Group, Kairos Biotech Team Up to Improve Transplant Success	Apr. 18	MT
Aptamer Group Files Patent Application for Optimer Binders	Apr. 08	MT
Aptamer submits patent application for Optimer binders	Apr. 08	AN
EARNINGS AND TRADING: Arbuthnot ups payout as profit more than doubles	Mar. 28	AN
Aptamer Group plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 28	CI
Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial	Mar. 25	MT
Transcript : Aptamer Group plc - Special Call	Mar. 21
Transcript : Aptamer Group plc - Pre Recorded Special Call	Mar. 12
Aptamer shares jump on successful Unilever contract progression	Mar. 11	AN
Aptamer Group, Unilever Prepare to Patent Optimers Developed Under Partnership	Mar. 11	MT
Aptamer says new Optimer+ delivers improved results	Feb. 27	AN
Aptamer Group plc Announces R&D Progress on New Optimer®? + Platform	Feb. 27	CI
Aptamer and Neuro-Bio begin Alzheimer's test development second phase	Feb. 22	AN
Aptamer Group, Neuro-Bio Enter Second Phase of Partnership for Alzheimer's Flow Test Development	Feb. 22	MT
Aptamer shares plunge as half-year revenue to fall by 70%	Feb. 05	AN
Aptamer Group plc Provides Revenue Guidance for the First Half of the Fiscal Year 2024	Feb. 05	CI
Zentek Announces "Positive" Therapeutic Results Achieved by Triera Biosciences for C19HBA	Jan. 30	MT
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	Jan. 17	MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	Jan. 17	MT
Aptamer inks deal for Optimer discovery with biotech firm	Dec. 14	AN

Chart Aptamer Group plc

Duration

Period

More charts

Company Profile

Aptamer Group plc is a United Kingdom-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA). Its Optimer platform supports a diverse portfolio of partners and technologies.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-10-14 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
APTAMER GROUP PLC	-32.61%	4.01M
VEEVA SYSTEMS INC.	+6.88%	33.82B
PRO MEDICUS LIMITED	+22.81%	7.85B
SECTRA AB	+31.37%	4.28B
EVOLENT HEALTH, INC.	-29.55%	2.64B
VERADIGM INC.	-27.55%	1.3B
LUNIT INC.	-30.53%	1.14B
SIMULATIONS PLUS, INC.	+11.69%	987M
B-SOFT CO.,LTD.	-35.42%	901M
SURGICAL SCIENCE SWEDEN AB	-20.93%	696M

Medical Software & Technology Services